Abstract Library

#3885 Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model

Introduction: Pancreatic neuroendocrine tumors (PNETs) are mostly indolent but can achieve malignancy. Surgery is the only approved first-line therapy. Kinase inhibitors and radiotherapy for unresectable PNETs are non-curative and targeted therapies are currently lacking for PNETs. However, immune checkpoint inhibitors have created a paradigm shift in cancer therapy with significant increase in overall survival, but are curative only in a subset of patients, partly due to limited T cell infiltration, especially in angiogenic and cold tumors like PNETs. Parallelly, antiangiogenic therapy increases lymphocyte infiltration by normalising the tumor vasculature. Tallying antiangiogenic to immunotherapies (AI) has provided improved survival benefits for patients of advanced RCCs and HCCs, while other cancers like glioblastoma remain highly resistant.

Conference:

Presenting Author:

Authors: John Robbert D, Guyot M, Killian T, Verslype C, Lambrechts D,

Keywords: Pancreatic neuroendocrine tumor, Antiangiogenic immunotherapy, single cell transcriptomics, Immunosuppression,

#2234 High Rate of Copy-Number Alterations in Gastrointestinal and Pancreatic Neuroendocrine Tumors with Unidentified Driver Mutations

Introduction: The driving genetic alteration leading to neuroendocrine tumor (NET) development has been reported for primary tumors of pancreatic origin, but not for metastases. Moreover, even for primary tumor a significant “dark matter” remains to be explored.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tirosh A

Authors: Tirosh A, Killian J, Zhu Y, Neychev V, Meltzer P,

Keywords: GEP-NET, Driver mutation, Copy-number, Metastases,